Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by New York Life Investment Management LLC

New York Life Investment Management LLC grew its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 4.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,469 shares of the company’s stock after acquiring an additional 494 shares during the period. New York Life Investment Management LLC’s holdings in Vaxcyte were worth $1,021,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Natixis Advisors LLC grew its stake in shares of Vaxcyte by 61.1% during the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after acquiring an additional 8,606 shares in the last quarter. Diversified Trust Co acquired a new stake in shares of Vaxcyte during the fourth quarter valued at about $1,433,000. Lisanti Capital Growth LLC grew its stake in Vaxcyte by 68.1% in the third quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock worth $3,715,000 after purchasing an additional 13,175 shares in the last quarter. Curi RMB Capital LLC acquired a new position in Vaxcyte in the third quarter worth about $903,000. Finally, WCM Investment Management LLC grew its stake in Vaxcyte by 52.6% in the third quarter. WCM Investment Management LLC now owns 140,847 shares of the company’s stock worth $15,935,000 after purchasing an additional 48,543 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total transaction of $710,240.00. Following the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at approximately $9,720,610.98. The trade was a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,616 shares of company stock valued at $5,225,971. Insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on PCVX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, February 26th. Guggenheim reiterated a “buy” rating and issued a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group started coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Stock Down 1.3 %

Shares of NASDAQ PCVX opened at $72.10 on Tuesday. The firm’s 50-day moving average price is $84.30 and its two-hundred day moving average price is $94.91. Vaxcyte, Inc. has a 52-week low of $58.10 and a 52-week high of $121.06. The stock has a market capitalization of $9.28 billion, a P/E ratio of -15.67 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. As a group, equities research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.